Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Extended Letrozole Therapy

PreclinicalSmall molecule

GGABRIEL MONTEIRO PINHEIRO

Extended Letrozole Therapy is one of 2 small molecule programs targeting Ovulation Induction. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovulation InductionRecruiting

Ovulation InductionPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Ovulation Induction

#DrugCompanyPhaseTrials

Mucinex

RReckitt Benckiser LLC

Extended Letrozole Therapy

GGABRIEL MONTEIRO PINHEIRO

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovulation Induction1 trial

Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)

Recruiting·GGABRIEL MONTEIRO PINHEIRO·N/A·NCT07159880·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Extended Letrozole Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Extended Letrozole Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Extended Letrozole Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GABRIEL MONTEIRO PINHEIRO company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGABRIEL MONTEIRO PINHEIRO

Related News